FibroBiologics, Inc. Announces Issuance of U.S. Patent Covering Fibroblast Cell Therapy for the Treatment of Osteoporosis

Stock Information for FibroBiologics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About FibroBiologics Inc.

The $45 Billion Cell Therapy Boom Just Hit a Manufacturing Milestone Most Investors Haven't Noticed
FibroBiologics Announces Advances in Burn Treatment Using Proprietary Fibroblast Spheroid Technology
FibroBiologics Completes Site Onboarding for Phase 1/2 Clinical Trial for CYWC628 for the Treatment of Refractory Diabetic Foot Ulcers
Cell Therapies Moving From Lab to Factory Floor, and the Stocks Behind Them
FibroBiologics to Present at the BIO Investment & Growth Summit
FibroBiologics Reports Full Year 2025 Financial Results and Provides Corporate Update
FibroBiologics' Chairman & CEO Pete O'Heeron Selected to Present at A4LI's H-SPAN Summit at Georgetown University
FibroBiologics Announces Issuance of Canadian Patent Covering Novel Fibroblast-Based Treatment for Cachexia

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.